Alkermes Plc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alkermes Plc. on May 12, 2026. The filing primarily serves to disclose a significant clinical development event regarding the company's investigational drug, LUMRYZ (sodium oxybate) extended-release oral suspension.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a clinical milestone rather than periodic financial results.
Material Changes and Clinical Results
On May 12, 2026, the Company announced positive topline results from the REVITALYZ SM study. Key details of the study include:
- Study Design: Double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 study.
- Investigational Product: LUMRYZ (sodium oxybate) extended-release oral suspension.
- Indication: Treatment of adults with idiopathic hypersomnia.
- Outcome: The results were described as positive compared to placebo.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) regarding the clinical results but does not contain specific forward-looking financial guidance, updated risk factors, or management commentary beyond the announcement of the positive topline data. The information in Item 7.01 and the associated press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the full press release (Exhibit 99.1) for specific statistical data and p-values associated with the REVITALYZ SM study.
- Verify the regulatory implications of the positive Phase 3 results for the potential approval of LUMRYZ for idiopathic hypersomnia.
- Monitor subsequent filings for any updates to the company's financial outlook or strategic plans resulting from this clinical success.